A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

NCT ID: NCT00943553

Last Updated: 2015-04-13

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-06-30

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of decitabine when used before chemotherapy to treat leukemia in pediatric patients. The study will also evaluate the ways decitabine is affected or changed when used in the human body.

Conditions

Acute Myelogenous Leukemia (AML)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Group Type: EXPERIMENTAL

decitabine Induction Chemotherapy

Intervention Type: DRUG

Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m\^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day)

2

Group Type: EXPERIMENTAL

Induction Chemotherapy

Intervention Type: DRUG

Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day only)

Interventions

decitabine Induction Chemotherapy

Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m\^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day)

Intervention Type: DRUG

Induction Chemotherapy

Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day only)

Intervention Type: DRUG

Other Intervention Names

E7373; E7373

Eligibility Criteria

Inclusion Criteria

1. Males and females, age 1 to16 years, inclusive

2. Females of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-hCG) at Visit 1 (Screening) and a negative urine pregnancy test prior to starting study drugs (Visit 2). Female subjects of childbearing potential must agree to be abstinent or to use a highly effective method of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, intrauterine devise (IUD), or have a vasectomised partner) for at least one menstrual cycle prior to starting study drug(s) and throughout the longer of either Core Study period or 30 days after the last dose of study drug. Those females using hormonal contraceptives must also be using an additional approved method of contraception (as described previously).

3. Sexually mature male patients who are not abstinent or have not undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use a highly effective method of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, IUD) starting for at least one menstrual cycle prior to starting study drug(s) and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously).

4. Diagnosis of acute myelogenous leukemia (AML)(bone marrow or peripheral blood blasts ≥ 20%)

5. Adequate cardiac function as defined by an echocardiogram or multiple gated acquisition (MUGA) scan demonstrating an ejection fraction within normal limits

6. Are willing and able to comply with all aspects of the protocol

7. Provide written informed consent from subject's guardian or legally authorized representative and child assent (if applicable)

Exclusion Criteria

1. Females who are pregnant (positive β-hCG test) or lactating

2. History of chronic myelogenous leukemia (CML) [t(9;22)]

3. Acute promyelocytic leukemia (M3 subtype in French-American-British [FAB] classification).

4. Known central nervous system (CNS) leukemia

5. AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome, or Diamond Blackfan anemia

6. White blood cell (WBC) count > 40,000/mm3

7. Serum creatinine > 2.5 mg/dL

8. Alanine aminotransferase (ALT) > 5 x upper limit of normal (ULN) and/or total bilirubin > 3 x ULN

9. Prior chemotherapy (other than hydroxyurea) or radiation therapy for AML

10. Known to be human immunodeficiency virus (HIV) positive

11. Any history of or concomitant medical condition that, in the opinion of the Investigator, would compromise the subject's ability to safely complete the study

12. The Investigator believes the subject to be medically unfit to receive the study drug or unsuitable for any other reason.

13. Subject with hypersensitivity to decitabine, daunorubicin, or cytarabine

14. Has participated in a drug trial in the last 4 weeks

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eisai Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peter Tarassoff, MD

Role: STUDY_DIRECTOR

Eisai Inc.

Locations

New Delhi, New Delhi, India

Countries

India

Other Identifiers

E7373-G000-201

Identifier Type: -

Identifier Source: org_study_id